Literature DB >> 12841385

Two cases of acute myeloblastic leukemia evolving from aplastic anemia.

Akihiko Taguchi1, Takayuki Tominaga, Yoshitaka Nakamori, Mutsuko Miyazaki, Kenji Shinohara.   

Abstract

Two cases of acute myeloblastic leukemia (AML) evolving from aplastic anemia are presented. The first case was diagnosed 18 years ago, and treatment with bolus methylprednisolone, prednisolone, and androgens resulted in partial hematological response. Severe pancytopenia recurred, and AML M0 by French-American-British classification developed. The second case was diagnosed 7 years ago. The patient had HLA DRB1*1501, and treatment with granulocyte colony-stimulating factor (G-CSF), cyclosporine, and methenolone resulted in complete hematological response. Thrombocytopenia recurred and did not respond to cyclosporine and methenolone or to later treatment with antithymocyte globulin, and AML M1 developed. Cytogenetic studies demonstrated 7q- in the first patient and +8 in the second patient. No mutations of N-ras or p53 were observed in either patient. These patients were treated with cytosine arabinoside, aclacinomycin, and G-CSF (CAG) chemotherapy, and the number of leukemic cells decreased substantially. However, pancytopenia after CAG chemotherapy persisted, and the first patient died of pneumonia and the second patient of cerebral hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841385     DOI: 10.1007/bf02986615

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  32 in total

Review 1.  The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated.

Authors:  N S Young
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

2.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases.

Authors:  M M Le Beau; R Espinosa; E M Davis; J D Eisenbart; R A Larson; E D Green
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

4.  Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia.

Authors:  F R Appelbaum; J Barrall; R Storb; R Ramberg; K Doney; G E Sale; E D Thomas
Journal:  Exp Hematol       Date:  1987-12       Impact factor: 3.084

5.  Long-term follow-up in patients with aplastic anemia. A study of 137 androgen-treated patients surviving more than two years. Joint Group for the Study of Aplastic and Refractory Anemias.

Authors:  Y Najean
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

6.  Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Elaine M Sloand; Olga Nunez; Neal S Young
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

7.  Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukaemia in adults.

Authors:  M M de Planque; H C Kluin-Nelemans; H J van Krieken; P M Kluin; A Brand; G C Beverstock; R Willemze; J J van Rood
Journal:  Br J Haematol       Date:  1988-09       Impact factor: 6.998

8.  A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.

Authors:  H Hirai; Y Kobayashi; H Mano; K Hagiwara; Y Maru; M Omine; H Mizoguchi; J Nishida; F Takaku
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

9.  Aplastic anaemia, acute myeloblastic leukaemia, and oxymetholone.

Authors:  I W Delamore; C G Geary
Journal:  Br Med J       Date:  1971-06-26

10.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Authors:  Hongbo Wang; Tatsuya Chuhjo; Shizuka Yasue; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.